尼日利亚埃努古地区肺结核患者利福平耐药结核的流行率。
Prevalence of rifampicin resistant tuberculosis among pulmonary tuberculosis patients In Enugu, Nigeria.
机构信息
Abia State University Faculty of Biological and Physical Sciences, Animal and Environmental Biology.
Abia State University, Microbiology.
出版信息
Afr Health Sci. 2022 Jun;22(2):156-161. doi: 10.4314/ahs.v22i2.18.
OBJECTIVE
We determined the prevalence of rifampicin resistance in pulmonary tuberculosis patients in Enugu Nigeria.
METHODS
A prospective hospital-based study involving 1300 presumptive multidrug-resistant tuberculosis patients was conducted in Enugu between April 2017 and 31st March, 2019.Participants age ranged from 15 years and older and each submitted one sputum specimens Sputum specimens were analyzed using the Gene Xpert MTB/RIF assay to detect resistance to rifampicin according to manufacturer's protocol.
RESULTS
The prevalence of rifampicin resistant tuberculosis was 6.8% (95% CI: 5.5- 8.3). Rifampicin resistance was significantly higher in males (9.0%) than females (4.2%) (P = 0.036< 0.05). Most of the cases were seen in the age group 35-44 years (28.4%). Prevalence of rifampicin resistant tuberculosis was 2.7% in treatment naive (new) patients and 4.1% in patients on anti-tuberculosis therapy (previously treated).
CONCLUSION
The prevalence of rifampicin resistant tuberculosis in Enugu was high. Rifampicin resistance in treatment naive (new) patients was also high. This study therefore highlights that active transmission of Multidrug-resistant tuberculosis among young males could be on-going.
目的
我们旨在确定尼日利亚埃努古的肺结核患者中利福平耐药的流行情况。
方法
这是一项在尼日利亚埃努古进行的前瞻性基于医院的研究，涉及 1300 名疑似耐多药肺结核患者。参与者的年龄在 15 岁及以上，每个人都提交了一份痰标本。痰标本采用 Gene Xpert MTB/RIF 检测法进行分析，根据制造商的方案检测利福平的耐药性。
结果
利福平耐药性肺结核的患病率为 6.8%（95%CI：5.5-8.3）。男性（9.0%）的利福平耐药率明显高于女性（4.2%）（P=0.036<0.05）。大多数病例发生在 35-44 岁年龄组（28.4%）。在初治（新）患者中，利福平耐药性肺结核的患病率为 2.7%，在接受抗结核治疗的患者（既往治疗）中为 4.1%。
结论
埃努古的利福平耐药性肺结核患病率较高。初治（新）患者的利福平耐药率也很高。因此，本研究表明，年轻男性中耐多药结核病的活跃传播可能正在进行。
Zotero 插件